拉贝洛尔联合硫酸镁治疗妊高征的疗效和对妊娠结局的影响分析  

Effect of labetalol combined with magnesium sulfate on pregnancy induced hypertension and pregnancy outcome

作　　者：毕凤 Bi Feng(Beijing Aerospace General Hospital,Beijing 100076)

机构地区：[1]北京航天总医院,北京100076

出　　处：《中国社区医师》2021年第26期6-7,共2页Chinese Community Doctors

摘　　要：目的:探讨拉贝洛尔联合硫酸镁治疗妊高征的疗效和对妊娠结局的影响。方法:2018年6月-2020年7月收治妊娠高症患者66例,依照用药方案不同分为两组,各33例。对照组采用硫酸镁治疗;试验组采用拉贝洛尔联合硫酸镁治疗。比较两组治疗效果。结果:试验组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);试验组治疗后舒张压、收缩压及尿蛋白水平均低于对照组,差异有统计学意义(P<0.05);试验组产妇产后2 h出血量及不良妊娠结局发生率均低于对照组,差异有统计学意义(P<0.05)。结论:采用拉贝洛尔联合硫酸镁治疗妊娠高血压产妇,更有助于降低患者血压水平,减少妊娠风险,降低不良妊娠结局发生率。Objective:To explore the effect of labetalol combined with magnesium sulfate on pregnancy induced hypertension and pregnancy outcome.Methods:From June 2018 to July 2020,66 patients with pregnancy induced hypertension were selected,and they were divided into two groups with 33 cases in each group according to different medication regimens.The control group was treated with magnesium sulfate.The experimental group was treated with labetalol combined with magnesium sulfate.We compared the treatment effect of the two groups.Results:The total effective rate of treatment in the experimental group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of diastolic blood pressure,systolic blood pressure and urinary protein in the experimental group were lower than those in the control group,the difference was statistically significant(P<0.05).In the experimental group,the amount of postpartum hemorrhage in 2 hours and adverse pregnancy outcome rate were lower than that of the control group,the difference was statistically significant(P<0.05).Conclusion:Using labetalol combined with magnesium sulfate in the treatment of pregnant women with pregnancy induced hypertension is more helpful to reduce the blood pressure level of patients,reduce the risk of pregnancy and reduce the incidence of adverse pregnancy outcomes.

关 键 词：硫酸镁 拉贝洛尔 妊娠合并高血压 妊娠结局 

分 类 号：R714.246[医药卫生—妇产科学]